Oryzon Genomics S.A. (LON:0RDB)

Market Cap	158.63M
Revenue (ttm)	11.81M
Net Income (ttm)	-3.40M
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,146
Average Volume	7,641
Open	2.490
Previous Close	2.325
Day's Range	2.375 - 2.925
52-Week Range	1.602 - 2.435
Beta	n/a
RSI	94.37
Earnings Date	Feb 26, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 46
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDB

Financial Performance

In 2023, Oryzon Genomics's revenue was $14.19 million, a decrease of -9.60% compared to the previous year's $15.70 million. Losses were -$3.35 million, -20.76% less than in 2022.

Financial numbers in USD